Shandong Xinhua Pharmaceutical Company Limited operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shandong Xinhua Pharmaceutical Company Limited with three other
companies in this sector in China:
Shenzhen Hepalink Pharmaceutical Group Co Ltd
sales of 4.81 billion Chinese Renmimbi [US$688.67 million]
of which 100%
was Pharmaceutical Manufacturing),
ChangChun High New Technology Industries
(5.32 billion Chinese Renmimbi [US$761.35 million]
of which 89%
was Medication), and
Changjiang Runfa Medicine Co Ltd
(4.67 billion Chinese Renmimbi [US$668.53 million]
of which 72%
During the year ended December of 2018, sales at
Shandong Xinhua Pharmaceutical Company Limited were 5.21 billion Chinese Renmimbi (US$744.93 million).
increase of 15.3%
versus 2017, when the company's sales were 4.52 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shandong Xinhua Pharmaceutical Company Limited
(and since 2013, sales have increased a total of 67%).
Sales of Pharmaceutical Intermediates and Others saw an increase
that was more than double the company's growth rate: sales were up
138.3% in 2018, from
569.01 million Chinese Renmimbi to 1.36 billion Chinese Renmimbi.
Shandong Xinhua Pharmaceutical Company Limited also saw significant increases in sales in
Preparations (up 30.0% to 2.58 billion Chinese Renmimbi)